Galectin-3 levels in children with cystic fibrosis

Ademhan Tural D., EMİRALİOĞLU ORDUKAYA N., AKIN Ş., Alboga D., Ozsezen B., Nayir Buyuksahin H., ...More

European Journal of Pediatrics, vol.183, no.5, pp.2333-2342, 2024 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 183 Issue: 5
  • Publication Date: 2024
  • Doi Number: 10.1007/s00431-024-05479-6
  • Journal Name: European Journal of Pediatrics
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, CINAHL, EMBASE
  • Page Numbers: pp.2333-2342
  • Keywords: Cystic fibrosis, Galectin-3, Inflammation, Neutrophil elastase, Pediatrics
  • Hacettepe University Affiliated: Yes


Cystic fibrosis (CF) is a multisystemic disease in which airway obstruction, infection, and inflammation play a critical role in the pathogenesis and progression of CF lung disease. The carbohydrate-binding protein Galectin-3 is increased in several inflammatory and fibrotic diseases and has recently been forwarded as a biomarker in these diseases. We aimed to define the role of serum Galectin-3 in children with CF by comparison with healthy subjects. This is a cross-sectional, case–control study. 143 CF and 30 healthy subjects were enrolled in the study. Peripheral blood and sputum concentrations of Galectins-3, interleukin (IL)-17A, IL-8, and neutrophil elastase (NE) were determined with commercial ELISA kits. There was no significant difference between the groups in age and gender (p = 0.592, p = 0.613, respectively). Serum Galectin-3 and NE concentrations were higher in the patient group than in healthy controls (p = 0.002, p < 0.001, respectively). There were no significant differences between groups according to IL-17A and IL-8 concentrations. Serum Galectin-3 was correlated with age (r = 0.289, p < 0.001) and body mass index (BMI) (r = 0.493, p < 0.001) in children with CF. Sputum Galectin-3 levels are negatively correlated with percent predictive forced expiratory volume in 1 s (FEV1) (r = − 0.297, p = 0.029), FEV1 z-score, (r = − 0.316, p = 0.020), percent predictive forced vital capacity (FVC) (r = − 0.347, p = 0.010), and FVC z-score (r = − 0.373, p = 0.006). Conclusion: The study shows that serum Galectin-3 levels increased in clinically stable CF patients, and serum Galectin-3 response may depend on age, gender, and BMI. The sputum Galectin-3 was found to be negatively correlated with patients’ lung functions. (Table presented.).